Physician profile
Johnny Miles
NPI 1487677514
$2,900.30
in general payments reported to CMS, 2019-2025
26 companies · $520 in 2025
The $520 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $228 · 2021: $552 · 2022: $418 · 2023: $358 · 2024: $246 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,124.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $660.37 | 2019-2024 | |
| Boston Scientific Corporation | $356.87 | 2019-2024 | Solyx Sis System |
| Astellas Pharma US INC | $353.54 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $292.39 | 2019-2024 | Injectafer |
| Mayne Pharma Commercial LLC | $185.07 | 2021-2025 | |
| Intuitive Surgical, INC. | $169.33 | 2025 | |
| Exeltis, USA INC. | $131.62 | 2020-2025 | Slynd |
| Hologic Sales and Service, LLC | $98.98 | 2022-2025 | Omni Hysteroscope, Acessa Provu System, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $90.76 | 2019-2022 | |
| Pfizer INC. | $87.24 | 2019-2022 | |
| Aspira Women'S Health INC | $76.80 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $43.28 | 2019-2021 | |
| Biogen, INC. | $42.63 | 2024-2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $41.07 | 2021-2022 | |
| Therapeuticsmd, INC. | $39.70 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $37.77 | 2019-2020 | |
| Shield Therapeutics INC | $37.36 | 2025 | |
| Avion Pharmaceuticals | $26.57 | 2019-2021 | |
| Lupin INC. | $24.98 | 2020-2021 | |
| Evofem Biosciences, INC. | $15.92 | 2021 | |
| Organon LLC | $15.77 | 2022 | |
| Coloplast Corp | $15.09 | 2021 | |
| Becton, Dickinson and Company | $14.93 | 2022 | |
| Merck Sharp & Dohme LLC | $14.63 | 2022 | |
| Millicent US INC | $13.92 | 2025 | Femring, Intrarosa |
| Coopersurgical, INC. | $13.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Miles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.